Examining the Application of Immune Checkpoint Inhibitors in Cancer Immunotherapeutic: A Systematic Review
DOI:
https://doi.org/10.54097/ga8k4z92Keywords:
Immune checkpoint inhibitors, cancer treatment, melanoma, non-small cell lung cancer, hepatocellular carcinoma.Abstract
To define the clinical utilizations, effectiveness, and challenges of immune checkpoint inhibitors (ICIs) in cancer treatments. A systematic review of the literatures regarding the efficacy of ICI therapy in the management of advanced melanoma, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC) was performed. The effectiveness and safety profile of anti-PD-1 (Nivolumab, Pembrolizumab, and Cemiplimab /PD-L1 (Atezolizumab, Durvalumab, and Avelumab), anti-CTLA-4 (Ipilimumab) drugs were measured and evaluated in several clinical trials via treatment-related indicators (response rate, survival rate, progression-free survival, overall survival, median overall survival, and treatment-related adverse events). Considering the increasing use of ICI therapy in days to come due to its great potential, this review can be valuable in assisting professional students or even oncologists to have a general overview of the role of ICIs in cancer immunotherapeutic, particularly targets the advanced melanoma, NSCLC, and HCC.
Downloads
References
Rotte, A., Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental & Clinical Cancer Research, 2019. 38 (1): p. 255.
Shiravand, Y., et al., Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol, 2022. 29 (5): p. 3044 - 3060.
Carlino, M.S., J. Larkin, and G.V. Long, Immune checkpoint inhibitors in melanoma. Lancet, 2021. 398 (10304): p. 1002 - 1014.
Hodi, F.S., et al., Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010. 363 (8): p. 711 - 23.
Tang, S., et al., Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects. Cells, 2022. 11 (3).
Wolchok, J.D., et al., Nivolumab plus Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2013. 369 (2): p. 122 - 133.
Borghaei, H., et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015. 373 (17): p. 1627 - 1639.
Brahmer, J., et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer. New England Journal of Medicine, 2015. 373 (2): p. 123 - 135.
Zheng, Y., et al., The progress of immune checkpoint therapy in primary liver cancer. Biochim Biophys Acta Rev Cancer, 2021. 1876 (2): p. 188638.
Baik, A. H., et al., Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. Clin Sci (Lond), 2021. 135 (5): p. 703 - 724.
Rapoport, B.L., et al., Pulmonary Toxicities Associated with the Use of Immune Checkpoint Inhibitors: An Update from the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. Frontiers in Pharmacology, 2021. 12.
Marini, A., et al., Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology, 2021. 96 (16): p. 754 - 766.
Nagasaki, J., T. Ishino, and Y. Togashi, Mechanisms of resistance to immune checkpoint inhibitors. Cancer Sci, 2022. 113 (10): p. 3303 - 3312.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
